Evidence map›Paper›PMID 26922650›Full record

ArticleWorld journal of urology2016

A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use.

Christian Beisland, Gigja Guðbrandsdottir, Lars A R Reisæter, Leif Bostad, Karin M Hjelle

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Renal cell carcinoma.World journal of urology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christian BeislandDepartment of Urology, Haukeland University Hospital, 5021, Bergen, Norway. christian.beisland@helse-bergen.no.ORCID http://orcid.org/0000-0002-3216-4937
Gigja GuðbrandsdottirDepartment of Urology, Haukeland University Hospital, 5021, Bergen, Norway.
Lars A R ReisæterDepartment of Radiology, Haukeland University Hospital, Bergen, Norway.
Leif BostadDepartment of Pathology, Haukeland University Hospital, Bergen, Norway.
Karin M HjelleDepartment of Urology, Haukeland University Hospital, 5021, Bergen, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn mid-2007, we introduced a new risk-stratified follow-up programme (FUP) for surgically treated localized renal cell carcinoma. After inclusion, the patients have been followed prospectively. In this study, we present the results in regard to stratification, completeness of the FUP and recurrences.

methodsThe FUP consists of three risk groups: low risk (LR), intermediate risk (IR) and high risk (HR), based on the risk stratification model introduced by Leibovich et al. (Cancer 97(7):1663-1671, 2003). In all risk groups, the patients are scheduled for ten follow-up visits (FUV) over 5 years, but seven, five and three FUVs, respectively, are outsourced to the patient's general practitioner (GP). Chest X-ray and abdomen CT are the imaging modalities used in the FUP.

resultsOf 312 included patients, 195 (62.5 %) had a complete FUP. However, in 86 patients the scheduled FUP had to be reduced, leaving 86.3 % of the remaining patients with a complete FUP. By including GPs, the number of FUVs at the hospital was reduced by ~60 %. The 5-year probability for freedom of recurrence is 0.98, 0.84 and 0.52 for the LR, IR and HR groups, respectively. Of 31 recurrences, 20 patients (65 %) were diagnosed within the FUP. Eleven patients (35 %) were diagnosed due to symptoms, and five of these had recurrences in locations not covered by standard imaging. Patients diagnosed within the FUP showed a better prognosis for survival and could in greater part receive tumour-directed treatment.

conclusionsAfter 8 years of clinical use, the outcome measures of the FUP seem to be within acceptable ranges.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Renal CellFemaleFollow-Up StudiesHumansKidney NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRisk AssessmentTime FactorsYoung AdultExternal validationFollow-upIntegrated staging systemsProspective evaluationRecurrenceRenal cell carcinomaRisk stratificationSurvival

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.